# Alnylam Pharmaceuticals, Inc. (ALNY) stock price

URL: https://funkfolio.com/stock/ALNY

> Alnylam Pharmaceuticals, Inc. (ALNY) trades at $156.50, is worth $20.96B, is priced at 7.9× earnings and scores 71/100. Valuation, financials and signals.

---

## Alnylam Pharmaceuticals, Inc. (ALNY)

Alnylam Pharmaceuticals, Inc. (ALNY) is a healthcare company (biotechnology) based in the United States. The share price is $156.50, down 2.02% on the day, which values the company at $20.96B. Price as of 17 Nov 2026, 22:46 UTC, from Yahoo Finance.

### Key facts

- **Share price:** $156.50 −2.02% today
- **Market value:** $20.96B
- **P/E ratio:** 7.9× last 12 months
- **Forward P/E:** 15.8×
- **Funk Score:** 71/100
- **Against its own history:** Well below its usual price usual price $428.08
- **200-week average:** $257.38 39% below
- **Sector:** Healthcare

Figures as of 17 Nov 2026, 22:46 UTC. Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.

### Alnylam Pharmaceuticals, Inc. in more detail

ALNY trades at 7.9× its last twelve months' earnings, 15.8× next year's expected earnings, 4.2× sales. Measured against its own history, the price is 63% below what its usual multiples would imply ($428.08) — well below its usual price. It sits 39% below its 200-week average of $257.38.

Over the last five fiscal years Alnylam Pharmaceuticals, Inc. has compounded revenue 49.8% a year. Its Funk Score is 71 out of 100 (financial strength 5.6, profitability 5.3, growth 10.0, value 7.6, each out of 10).

In its favour: Operating margin is expanding; Five straight years of revenue growth. Worth checking: Share count keeps rising; Thin interest cover.

4 of the superinvestors tracked here hold ALNY, including Baillie Gifford team (1.3% of the portfolio), Dodge & Cox team (0.3% of the portfolio), David Shaw (founder) (0.2% of the portfolio).

### Superinvestors holding ALNY

4 of the investors tracked here report a position in their latest 13F filing.

- [Baillie Gifford team Baillie Gifford & Co](https://funkfolio.com/gurus/baillie-gifford) 1.28% of portfolio · $1.4B · added · Q3 2026
- [Dodge & Cox team Dodge & Cox](https://funkfolio.com/gurus/dodge-and-cox) 0.27% of portfolio · $495.1M · added · Q3 2026
- [David Shaw (founder) D. E. Shaw & Co.](https://funkfolio.com/gurus/david-shaw) 0.21% of portfolio · $332.4M · added · Q2 2026
- [Ray Dalio (founder) Bridgewater Associates](https://funkfolio.com/gurus/bridgewater) 0.12% of portfolio · $30M · trimmed · Q2 2026

### Health Care companies of similar size

- [STERIS STE](https://funkfolio.com/stock/STE)
- [Insmed INSM](https://funkfolio.com/stock/INSM)
- [United Therapeutics UTHR](https://funkfolio.com/stock/UTHR)
- [Incyte INCY](https://funkfolio.com/stock/INCY)
- [Viatris VTRS](https://funkfolio.com/stock/VTRS)
- [Tenet Healthcare THC](https://funkfolio.com/stock/THC)
- [BioNTech BNTX](https://funkfolio.com/stock/BNTX)
- [Guardant Health GH](https://funkfolio.com/stock/GH)
- [Zimmer Biomet Holdings ZBH](https://funkfolio.com/stock/ZBH)
- [Medpace Holdings MEDP](https://funkfolio.com/stock/MEDP)
- [Revvity RVTY](https://funkfolio.com/stock/RVTY)
- [Exelixis EXEL](https://funkfolio.com/stock/EXEL)

Side by side: [ALNY vs ZBH (Alnylam Pharmaceuticals, Inc. vs Zimmer Biomet Holdings)](https://funkfolio.com/compare/alny-vs-zbh) [ALNY vs GH (Alnylam Pharmaceuticals, Inc. vs Guardant Health)](https://funkfolio.com/compare/alny-vs-gh) [ALNY vs BNTX (Alnylam Pharmaceuticals, Inc. vs BioNTech)](https://funkfolio.com/compare/alny-vs-bntx) [ALNY vs MEDP (Alnylam Pharmaceuticals, Inc. vs Medpace Holdings)](https://funkfolio.com/compare/alny-vs-medp) [ALNY vs THC (Alnylam Pharmaceuticals, Inc. vs Tenet Healthcare)](https://funkfolio.com/compare/alny-vs-thc)

[All health care companies by market value](https://funkfolio.com/companies/sector/health-care) [Largest companies in the United States](https://funkfolio.com/companies/country/united-states) [All stocks A–Z](https://funkfolio.com/stocks)

### Alnylam Pharmaceuticals, Inc. (ALNY): questions and answers

**What is ALNY's P/E ratio?**

Alnylam Pharmaceuticals, Inc. trades at 7.9× its last twelve months' earnings and 15.8× next year's expected earnings.

**What is ALNY's PEG ratio?**

Alnylam Pharmaceuticals, Inc.'s PEG ratio is 0.22 — its P/E divided by its expected earnings growth. Around 1 is the classic sign of a price that matches the growth; well above it means the growth is being paid for in advance.

**What is Alnylam Pharmaceuticals, Inc.'s market cap?**

Alnylam Pharmaceuticals, Inc. is valued at $20.96B at a share price of $156.50.

**Is ALNY overvalued or undervalued?**

Against its own history, ALNY is well below its usual price: the price is 63% below the $428.08 implied by the median multiples it has traded at (price / sales, price / book). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.

**Is ALNY above its 200-week moving average?**

No. ALNY is 39.2% below its 200-week average of $257.38. Long-term investors watch that line because strong companies rarely trade below it for long.

**How fast is Alnylam Pharmaceuticals, Inc. growing?**

Over the last five fiscal years Alnylam Pharmaceuticals, Inc.'s revenue grew 49.8% a year.

### Learn to read these numbers

[All stocks guides →](https://funkfolio.com/learn/stocks)

- [Altman Z-score: formula, zones and where it fails](https://funkfolio.com/learn/stocks/altman-z-score)

  The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- [Analyst price targets and ratings: what they mean](https://funkfolio.com/learn/stocks/analyst-price-targets)

  An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
- [Free cash flow and FCF yield explained](https://funkfolio.com/learn/stocks/free-cash-flow)

  Free cash flow is the cash a business generates from operations minus what it spends on equipment, buildings and other long-lived assets. Free-cash-flow yield divides that cash by the company's market value: $5 billion of free cash flow on a $100 billion company is a 5% yield. It is cash available to owners and lenders, not profit.

### Cite this page

Funkfolio, “Alnylam Pharmaceuticals, Inc. (ALNY) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/ALNY

Underlying data: Yahoo Finance; company filings with the SEC.
